Serina Therapeutics Inc Market Cap ($17.80 Million)
Market Cap & Net Worth: Serina Therapeutics Inc (SER)
Serina Therapeutics Inc market cap. Serina Therapeutics Inc (NYSE MKT:SER) has a market capitalization of $17.80 Million ($17.80 Million) as of November 1, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #25341 globally and #5376 in its home market, demonstrating a 15.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Serina Therapeutics Inc's stock price $1.98 by its total outstanding shares 10785564 (10.79 Million). Also see Serina Therapeutics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Serina Therapeutics Inc Market Cap History (2018–2026)
Serina Therapeutics Inc market cap history from 2018 to 2026. Data shows change from $1.15 Billion to $21.36 Million (-40.54% CAGR). Check Serina Therapeutics Inc stock quote for real-time trading data and today's change.
Serina Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Serina Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Serina Therapeutics Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1086.26x
Serina Therapeutics Inc's market cap is 1086.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.15 Billion | $1.40 Million | -$7.50 Million | 825.03x | N/A |
| 2019 | $701.06 Million | $1.73 Million | -$12.15 Million | 405.71x | N/A |
| 2020 | $585.50 Million | $54.00K | -$10.87 Million | 10842.63x | N/A |
| 2021 | $419.87 Million | $3.04 Million | -$1.26 Million | 138.15x | N/A |
| 2022 | $212.63 Million | $500.00K | -$2.68 Million | 425.26x | N/A |
| 2023 | $148.30 Million | $3.15 Million | $5.27 Million | 47.04x | 28.15x |
| 2024 | $60.83 Million | $56.00K | -$11.14 Million | 1086.26x | N/A |
Competitor Companies of SER by Market Capitalization
Companies near Serina Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see Serina Therapeutics Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Serina Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Serina Therapeutics Inc (2018–2026)
Market capitalization of Serina Therapeutics Inc from 2018 to today. Between 2018 and today, Serina Therapeutics Inc's market cap moved from $1.15 Billion to $ 21.36 Million, with a yearly change of -40.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $21.36 Million | +3.50% |
| 2025 | $20.63 Million | -66.08% |
| 2024 | $60.83 Million | -58.98% |
| 2023 | $148.30 Million | -30.25% |
| 2022 | $212.63 Million | -49.36% |
| 2021 | $419.87 Million | -28.29% |
| 2020 | $585.50 Million | -16.48% |
| 2019 | $701.06 Million | -39.13% |
| 2018 | $1.15 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Serina Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.80 Million USD |
| MoneyControl | $17.80 Million USD |
| MarketWatch | $17.80 Million USD |
| marketcap.company | $17.80 Million USD |
| Reuters | $17.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more